Literature DB >> 35482946

Preventing invasive meningococcal disease in early infancy.

Jessica Presa1, Lidia Serra2, Catherine Weil-Olivier3, Laura York4.   

Abstract

This review considers the pathogenesis, diagnosis, and epidemiology of invasive meningococcal disease in infants, to examine and critique meningococcal disease prevention in this population through vaccination. High rates of meningococcal disease and poor outcomes, particularly for very young infants, highlight the importance of meningococcal vaccination in early infancy. Although effective and safe meningococcal vaccines are available for use from 6 weeks of age, they are not recommended globally. Emerging real-world data from the increased incorporation of these vaccines within immunization programs inform recommendations regarding effectiveness, appropriate vaccination schedule, possible long-term safety effects, and persistence of antibody responses. Importantly, to protect infants from IMD, national vaccination recommendations should be consistent with available data regarding vaccine safety, effectiveness, and disease risk.

Entities:  

Keywords:  Infant; maternal vaccination; meningococcal; passive immunity; vaccination

Mesh:

Substances:

Year:  2022        PMID: 35482946      PMCID: PMC9196819          DOI: 10.1080/21645515.2021.1979846

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  78 in total

Review 1.  Development of natural immunity to Neisseria meningitidis.

Authors:  A J Pollard; C Frasch
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

Review 2.  Vaccination greatly reduces disease, disability, death and inequity worldwide.

Authors:  F E Andre; R Booy; H L Bock; J Clemens; S K Datta; T J John; B W Lee; S Lolekha; H Peltola; T A Ruff; M Santosham; H J Schmitt
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

3.  Safety of MenACWY-CRM vaccine exposure during pregnancy.

Authors:  Tracy A Becerra-Culqui; Lina S Sy; Bradley K Ackerson; Lie Hong Chen; Christine A Fischetti; Zendi Solano; Johannes E Schmidt; Lucio Malvisi; Carlo Curina; Michele Pellegrini; Hung Fu Tseng
Journal:  Vaccine       Date:  2020-02-10       Impact factor: 3.641

4.  Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study.

Authors:  Manish Sadarangani; David W Scheifele; Scott A Halperin; Wendy Vaudry; Nicole Le Saux; Raymond Tsang; Julie A Bettinger
Journal:  Clin Infect Dis       Date:  2015-01-20       Impact factor: 9.079

5.  Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016.

Authors:  Lucy A McNamara; Jennifer Dolan Thomas; Jessica MacNeil; How Yi Chang; Michael Day; Emily Fisher; Stacey Martin; Tasha Poissant; Susanna E Schmink; Evelene Steward-Clark; Laurel T Jenkins; Xin Wang; Anna Acosta
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

Review 6.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

Review 7.  IgG placental transfer in healthy and pathological pregnancies.

Authors:  Patricia Palmeira; Camila Quinello; Ana Lúcia Silveira-Lessa; Cláudia Augusta Zago; Magda Carneiro-Sampaio
Journal:  Clin Dev Immunol       Date:  2011-10-01

8.  Global epidemiology of invasive meningococcal disease.

Authors:  Rabab Z Jafri; Asad Ali; Nancy E Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar A Bhutta; Jon Abramson
Journal:  Popul Health Metr       Date:  2013-09-10

9.  Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.

Authors:  G L Lawrence; H Wang; M Lahra; R Booy; P B McINTYRE
Journal:  Epidemiol Infect       Date:  2016-04-20       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.